MedTrace Logo

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-04

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Conditions

Interventions

DRUG

Cevostamab

Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.

DRUG

Elranatamab

Elranatamab solution for injection will be administered SC as specified in each treatment arm.

DRUG

Tocilizumab

Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • Australia
  • Israel
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05927571 on ClinicalTrials.gov